List of Austedo drug patents
Austedo is owned by Teva Branded Pharm.
Austedo contains Deutetrabenazine.
Austedo has a total of 17 drug patents out of which 0 drug patents have expired.
Austedo was authorised for market use on 03 April, 2017.
Austedo is available in tablet;oral dosage forms.
Austedo can be used as a method of treating huntington's chorea, treatment of tardive dyskinesia; a method of treating huntington's chorea, treatment of tardive dyskinesia.
Drug patent challenges can be filed against Austedo from October, 2023.
The generics of Austedo are possible to be released after 15 September, 2038.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8524733 | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(8 years from now) | |
| US9550780 | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8524733
(Pediatric) | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Oct, 2031
(8 years from now) | |
| US9814708 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(10 years from now) | |
| US9296739 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(10 years from now) | |
| US9233959 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(10 years from now) | |
|
US9550780
(Pediatric) | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(11 years from now) | |
|
US9814708
(Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(11 years from now) | |
|
US9233959
(Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(11 years from now) | |
|
US9296739
(Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(11 years from now) | |
| US11446291 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(13 years from now) | |
| US10959996 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(13 years from now) | |
| US11357772 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(13 years from now) | |
|
US11357772
(Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(13 years from now) | |
|
US10959996
(Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(13 years from now) | |
| US11179386 | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(15 years from now) | |
|
US11179386
(Pediatric) | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 3, 2024 |
| New Chemical Entity Exclusivity (NCE) | Apr 3, 2022 |
| M | Jun 24, 2024 |
| Pediatric Exclusivity (PED) | Oct 3, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
NCE-1 date: October, 2023
Market Authorisation Date: 03 April, 2017
Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic